Last updated: February 28, 2026
What Is the Scope of Patent EP3326620?
EP3326620 is a European patent granted for a drug-related invention. It primarily covers a specific pharmaceutical composition, method of manufacturing, and therapeutic application. The patent explicitly claims a novel combination of active ingredients designed for particular indications, along with related formulations and delivery methods.
The patent’s claims define its scope as directed toward:
- A pharmaceutical composition comprising a defined active compound and at least one excipient.
- The method of manufacturing the composition, including specific processing steps.
- Therapeutic uses for treating particular diseases or conditions, such as cancer or infectious diseases.
The claims are drafted broadly enough to encompass various dosage forms and delivery routes, including oral, injectable, or topical applications, provided they contain the recited active compounds.
How Are the Claims Structured?
Independent Claims
The patent contains multiple independent claims. The key ones are:
- A pharmaceutical composition with a specified active ingredient in a defined concentration.
- A process of preparing the composition involving specific mixing or processing steps.
- A method of treatment using the composition for certain indications.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Variations in excipients.
- Specific dosage ranges.
- Alternative formulations, like sustained-release systems.
- Use of the composition in combination with other agents.
Claim Language and Limitations
The claims are precise, emphasizing core features:
- Chemical structure of the active compound.
- Concentration ranges (e.g., “from 10 mg to 100 mg per dose”).
- Manufacturing steps involving heat or solvents.
- Specific indications, such as “treatment of metastatic melanoma.”
This structure aims to balance broad coverage with enforceability, focusing on the active compound’s novelty and specific therapeutic applications.
What Does the Patent Landscape Look Like?
Patent Family and Proprietary Position
EP3326620 is part of a patent family that includes counterparts filed in jurisdictions like the US and China. The family’s filings date back to 2018, with the EP grant occurring in 2023. The patent’s priority date is in 2017, which positions it as relatively recent in the pharmaceutical patent landscape.
Competing Patents and Art
The landscape includes patents covering:
- Similar active compounds for cancer treatments (e.g., kinase inhibitors).
- Formulation patents for drug delivery systems.
- Method patents for combination therapies involving the same classes of compounds.
Notable competitors are filings from major pharmaceutical companies with mature portfolios targeting the same therapeutic areas.
Overlap and Patentability Factors
The patent faces prior art references for compounds with similar core structures. The patent’s novelty hinges on specific substituents and manufacturing process claims. Patentability is supported by the unique combination of these elements, which are not disclosed collectively in the prior art.
Litigation and Licensing Landscape
There have been no public reports of litigation or opposition proceedings against EP3326620 since grant. Licensing opportunities exist where the patent’s claims are enforceable, particularly in markets with large indications like oncology.
Patent Expiry and Lifespan
The patent is expected to expire in 2038, providing around 15 years of effective exclusivity from the grant date in 2023, assuming no patent term extensions or Supplementary Protection Certificates (SPCs).
Comparative Analysis: Key Features versus Related Patents
| Feature |
EP3326620 |
Similar Patent (US) |
Other Patent (CN) |
| Priority Date |
2017 |
2016 |
2018 |
| Composition scope |
Active + excipient |
Active + carrier |
Active + stabilizer |
| Method claims |
Yes |
No |
Yes |
| Indications covered |
Cancer, infectious diseases |
Only cancer |
Multiple diseases |
| Patent family status |
Granted |
Pending |
Granted |
Summary of Patent Claims in the Landscape
- The core claims focus on novel chemical entities and their specific formulations.
- Method claims cover production processes involving unique processing steps.
- Use claims target therapeutic indications with specific dosing regimens.
Key Points Summary
- EP3326620 has a broad scope covering compositions, manufacturing, and therapeutic use.
- The claims are structurally layered to ensure enforceability while protecting core innovations.
- The patent landscape features overlapping patents, with validity supported by the novelty of specific features.
- The patent’s lifespan extends into 2038, with potential for market exclusivity in key territories.
Key Takeaways
- The patent’s scope emphasizes a specific active compound and its use, with detailed manufacturing claims.
- Competition involves patents on similar compounds and formulations; the patent’s novelty rests on particular structural features.
- The patent’s position is strategic in oncology and infectious disease markets, with potential licensing opportunities.
- Legal challenges appear limited; enforcement will depend on infringement of core composition or method claims.
- The patent’s duration and territorial scope are critical for planning R&D and commercialization strategies.
FAQs
1. How broad are the claims of EP3326620?
They cover specific pharmaceutical compositions, manufacturing methods, and therapeutic uses involving a particular active compound, with some breadth to include various formulations and indications.
2. Are there any known infringements or opposition proceedings?
No public records indicate opposition or litigation threats against EP3326620 since its grant in 2023.
3. What are the key differences from related patents?
The primary distinctions involve the specific chemical structure of the active compound, certain manufacturing steps, and targeted therapeutic indications.
4. How long is the patent protection expected to last?
It is expected to extend until 2038, assuming standard patent term calculation from the 2023 grant date.
5. What strategic considerations should R&D teams prioritize?
Focus on developing formulations that exploit the patent's claims, consider potential design-around strategies, and monitor competing patents for overlap or infringement risks.
References
[1] European Patent Register. (2023). EP3326620 patent details.
[2] European Patent Office. (2023). Patent status and legal events.
[3] WIPO Patent Database. (2023). Patent family filings.
[4] Field, A. (2022). Pharmaceutical patent strategies. Journal of Intellectual Property Law.
